Total Payments
$9,073
2024 Payments
$65.13
Companies
70
Transactions
536
Medicare Patients
18,556
Medicare Billing
$2.3M
Payment Breakdown by Category
Food & Beverage$8,729 (96.2%)
Education$343.51 (3.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,729 | 527 | 96.2% |
| Education | $343.51 | 9 | 3.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $762.70 | 51 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $741.66 | 50 | $0 (2023) |
| Amgen Inc. | $657.76 | 32 | $0 (2023) |
| Lilly USA, LLC | $649.78 | 31 | $0 (2023) |
| Merck Sharp & Dohme LLC | $595.33 | 36 | $0 (2023) |
| Genentech USA, Inc. | $477.78 | 36 | $0 (2023) |
| Janssen Biotech, Inc. | $441.90 | 27 | $0 (2023) |
| Eisai Inc. | $380.35 | 19 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $298.89 | 13 | $0 (2023) |
| PFIZER INC. | $296.12 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65.13 | 4 | ABBVIE INC. ($31.28) |
| 2023 | $1,925 | 87 | Merck Sharp & Dohme LLC ($196.26) |
| 2022 | $1,067 | 56 | Novartis Pharmaceuticals Corporation ($172.71) |
| 2021 | $1,004 | 58 | Lilly USA, LLC ($140.99) |
| 2020 | $989.59 | 62 | Amgen Inc. ($121.67) |
| 2019 | $1,266 | 77 | Amgen Inc. ($274.74) |
| 2018 | $1,430 | 99 | Novartis Pharmaceuticals Corporation ($198.92) |
| 2017 | $1,326 | 93 | Genentech USA, Inc. ($273.82) |
All Payment Transactions
536 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: DESMOID TUMORS | ||||||
| 04/01/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Education | Cash or cash equivalent | $6.11 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 02/24/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $26.77 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Oncology | ||||||
| 11/08/2023 | G1 Therapeutics, Inc. | COSELA (Drug) | Food and Beverage | Cash or cash equivalent | $17.09 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.07 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Oncology | ||||||
| 10/18/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: Oncology | ||||||
| 10/17/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Oncology | ||||||
| 10/11/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Oncology | ||||||
| 10/05/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $30.13 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/21/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Oncology | ||||||
| 09/19/2023 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.13 | General |
| Category: Oncology | ||||||
| 09/14/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.53 | General |
| Category: Hematology | ||||||
| 09/07/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.34 | General |
| Category: Oncology | ||||||
| 09/05/2023 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $99.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 2,412 | 64,857 | $1.0M | $242,254 |
| 2022 | 50 | 4,197 | 81,070 | $2.2M | $640,719 |
| 2021 | 63 | 5,821 | 108,141 | $2.1M | $618,340 |
| 2020 | 74 | 6,126 | 130,840 | $2.6M | $792,460 |
Total Patients
18,556
Total Services
384,908
Medicare Billing
$2.3M
Procedure Codes
216
All Medicare Procedures & Services
216 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 31 | 7,430 | $170,890 | $43,940 | 25.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 2,220 | $113,220 | $40,542 | 35.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 137 | 208 | $98,592 | $27,547 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 206 | 255 | $86,445 | $23,725 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 187 | 236 | $56,404 | $15,151 | 26.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 144 | $54,432 | $13,910 | 25.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 556 | 1,609 | $14,481 | $13,516 | 93.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 38 | 33,150 | $132,600 | $13,095 | 9.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 560 | 1,597 | $46,313 | $12,153 | 26.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 75 | 158 | $29,862 | $7,201 | 24.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $27,495 | $6,449 | 23.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 12 | 4,160 | $20,800 | $5,751 | 27.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 91 | 398 | $27,462 | $4,113 | 15.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 71 | 242 | $14,762 | $2,792 | 18.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 14 | 44 | $7,832 | $2,148 | 27.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 25 | 86 | $7,224 | $1,862 | 25.8% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 17 | 9,300 | $46,500 | $1,519 | 3.3% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 33 | 82 | $4,838 | $1,395 | 28.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 60 | $4,740 | $1,263 | 26.7% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 31 | 45 | $7,020 | $1,244 | 17.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 14 | 14 | $4,816 | $928.54 | 19.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 19 | 730 | $20,440 | $635.12 | 3.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 19 | 39 | $2,184 | $579.38 | 26.5% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 44 | 98 | $1,078 | $307.48 | 28.5% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 17 | 1,450 | $1,450 | $160.90 | 11.1% |
About Dr. Mark Robbins, MD
Dr. Mark Robbins, MD is a Hematology & Oncology healthcare provider based in Cranston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265442206.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Robbins, MD has received a total of $9,073 in payments from pharmaceutical and medical device companies, with $65.13 received in 2024. These payments were reported across 536 transactions from 70 companies. The most common payment nature is "Food and Beverage" ($8,729).
As a Medicare-enrolled provider, Robbins has provided services to 18,556 Medicare beneficiaries, totaling 384,908 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 216 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cranston, RI
- Active Since 08/09/2006
- Last Updated 04/17/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1265442206
Products in Payments
- OPDIVO (Biological) $638.18
- KEYTRUDA (Biological) $501.10
- Lenvima (Drug) $271.03
- VERZENIO (Drug) $264.39
- CYRAMZA (Drug) $182.86
- Nplate (Biological) $176.56
- TECENTRIQ (Biological) $171.86
- XTANDI (Drug) $171.48
- JAKAFI (Drug) $157.14
- KISQALI (Drug) $154.16
- Enhertu (Drug) $147.56
- TASIGNA (Drug) $143.09
- IMBRUVICA (Drug) $130.26
- IBRANCE (Drug) $123.15
- ERLEADA (Drug) $120.28
- GILOTRIF (Drug) $112.83
- Cabometyx (Drug) $111.92
- BRUKINSA (Drug) $111.63
- ELIQUIS (Drug) $110.59
- Halaven (Drug) $109.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cranston
Dr. Plakyil Joseph, M.d, M.D
Hematology & Oncology — Payments: $23,585
Hematology & Oncology $23,585
Sundaresan Sambandam, M.d, M.D
Hematology & Oncology — Payments: $6,926
Hematology & Oncology $6,926
Ayesha Hassan, Md, MD
Hematology & Oncology — Payments: $376.35
Hematology & Oncology $376.35
Dr. Fatima Raza, M.d, M.D
Hematology & Oncology — Payments: $59.12
Hematology & Oncology $59.12